>AXS-05 is a novel, oral, investigational drug product under development for the treatment of central nervous system (CNS) disorders. >AXS-05 utilizes Axsome’s technology of combining bupropion and dextromethorphan (DM). >bupropion and dextromethorphan for both the treatment of agitation associated with Alzheimer’s Disease (AD) and Treatment Resistant Depression >Fast Track designation by the FDA ШТА https://axsome.com/axs-pipeline/about-axs-05/